GlassScriptPhysician profile
Jared M Lechtenstein
NPI 1912922469
$15,699.59
in general payments reported to CMS, 2019-2025
39 companies · $2,333 in 2025
The $2,333 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,472 · 2020: $1,592 · 2021: $1,866 · 2022: $2,658 · 2023: $3,245 · 2024: $2,533 · 2025: $2,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,611 · Consulting Fee: $400 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,610.95 |
| Consulting Fee | $400.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $2,380.37 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,284.41 | 2019-2025 | Jardiance |
| Amgen INC. | $1,163.92 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $1,156.16 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $1,090.62 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $964.43 | 2019-2024 | Xarelto |
| Heartflow, INC. | $949.89 | 2022-2025 | Ffrct |
| Abbott Laboratories | $716.17 | 2019-2023 | Jot Dx |
| Astrazeneca Pharmaceuticals LP | $696.36 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $683.21 | 2021-2025 | Watchman Flx, Watchman Access System, Resonate El Icd Vr |
| Pfizer INC. | $666.54 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $609.50 | 2019-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $597.40 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Edwards Lifesciences Corporation | $389.70 | 2020-2025 | |
| Amarin Pharma, INC. | $370.96 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Lechtenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.